Swiss drug giant Novartis AG reported Tuesday a decline in its first-quarter net profit with weak sales mainly due to negative impact of generic competition and pricing. However, core earnings per share topped analysts' estimates. Further, the company backed its fiscal 2017 forecast. Novartis shares were gaining around 3 percent in the morning trading in Zurich.
from RTT - Earnings http://ift.tt/2pgsBW6
via IFTTT
No comments:
Post a Comment